Healthy Returns: Here are the drugmakers with new U.S. investments as Trump’s pharma tariffs loom
Tariff threats are fueling a new wave of U.S. manufacturing investments from the pharmaceutical industry.
You are not logged in so some information on this page has been withheld. To see more, please log in.